A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: A meta-analysis

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 8, 2013, Pages 1417-1424

  Xu, Cheng ^a   Yan, Zhehui ^a   Zhou, Liang ^a   Wang, Yuming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AFP; Diagnostic accuracy; GPC3; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; GLYPICAN 3;

CANCER LOCALIZATION; CANCER STAGING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; META ANALYSIS; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ALPHA-FETOPROTEINS; AREA UNDER CURVE; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; LIVER NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84880920917     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1458-5     Document Type: Review

References (46)

1. Beale G et al (2008) AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8:200
2. Bertino G et al (2012) Hepatocellualar carcinoma serum markers. Semin Oncol 39(4):410-433
3. Bh Y (2001) Chinese society of liver cancer: clinical diagnosis and staging criteria for primary hepatocellular carcinoma. Zhongguo Ganzangbing Zazhi 9:324-330
4. Bian YZ et al (2011) Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 19(4):260-265
5. Capurro M, Filmus J (2005) Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 65(1):372 (author reply 372-3)
6. Capurro M et al (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89-97
7. Capurro MI et al (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65(14):6245-6254
8. Cleophas TJ, Zwinderman AH (2009) Meta-analyses of diagnostic studies. Clin-Chem-Lab-Med 47(11):1351-1354
9. Dinnes J et al (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1-113
10. Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917
11. Filmus J, Capurro M (2004) Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 8(4):207-212
12. Filmus J, Selleck SB (2001) Glypicans: proteoglycans with a surprise. J Clin Invest 108:497-501
13. Honest H, Khan KS (2002) Reporting of measures of accuracy in systematic reviews of diagnostic literature. BMC Health Serv Res 2:4
14. Huber R et al (1999) DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1. Proc Natl Acad Sci USA 96(2):616-621
15. Komori H et al (2010) Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma. Nihon Rinsho 68(Suppl 7):833-836
16. Li BD et al (2006) Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi 44(7):458-462
17. Li P et al (2009) Diagnosis of Glypican-3 protein for primary hepatic cancer is superior to alpha-fetoprotein. Hep Intl 3(1):155
18. Li P et al (2010) Diagnostic value of serum AFP alone or in combination with glypican 3, VEGF or IGF-II for patients with primary hepatocellular carcinoma. World J Gastroenterol
19. Liu H et al (2010) Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 16(35):4410-4415
20. Malaguarnera G et al (2010) Serum markers of hepatocellular carcinoma. Dig Dis Sci 55(10):2744-2755
21. Miao H et al (2007) Glypican-3 protein expression in serum and tissues and its clinical significance in hepatocellular carcinoma. World Chin J Digestol 15(21):2311-2315
22. Midorikawa Y et al (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103(4):455-465
23. Moety HAAE et al (2011) Glypican-3 amino terminal marker for early detection of HCC. Hep Intl 5(1):435
24. Moriguchi H, Sato C (2004) The values and limitations of glypican-3 as a novel tumor marker for hepatocellular carcinoma from clinical and economic viewpoints. Gastroenterology 127(2):679-680
25. Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12(14):1293-1316
26. Nakatsura T, Nishimura Y (2005) Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19(2):71-77
27. Nakatsura T et al (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306(1):16-25
28. Nobuoka D et al (2010) Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 24(2):521-528
29. Ozkan H et al (2011) Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 25(5):350-353
30. Qiao SS et al (2011) Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 58(110-111):1718-1724
31. Song F et al (2002) Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 31(1):88-95
32. Sousa MR, Ribeiro AL (2009) Systematic review and meta-analysis of diagnostic and prognostic studies: a tutorial. Arq Bras Cardiol 92(3): 229-238, 235-245
33. Sung YK et al (2003) Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94(3):259-262
34. Suzuki M et al (2010) Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res 30(12):5055-5061
35. Tangkijvanich P et al (2010) Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 25(1):129-137
36. Wei Z et al (2007) Detection of glypican 3 in serum and its clinical significance on the diagnosis of hepatocellular carcinoma. Tumor 27(9):679-682
37. Whiting P et al (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25
38. Whiting P et al (2004) Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 140(3):189-202
39. Yamauchi N et al (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18(12):1591-1598
40. Yan D et al (2011) Detection of alpha-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal 25(2):113-117
41. Yao M et al (2011) Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 10(3):289-294
42. Yasuda E et al (2010) Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 40(5):477-485
43. Youssef MF et al (2010) Clinical utility of Glypican- 3 in hepatocellular carcinoma. Int J Integr Biol 10(1):41-47
44. Zamora J et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31
45. Zhang Q et al (2010) Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 43(12):1003-1008
46. Zhu ZW et al (2001) Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48(4):558-564